Si-Bone Inc is a medical technology company focused on developing and commercializing innovative solutions for the treatment of musculoskeletal conditions, particularly those affecting the sacroiliac joint. The company specializes in minimally invasive surgical techniques and instruments that aim to alleviate pain and restore function for patients suffering from various spinal disorders. By leveraging advanced technology and evidence-based practices, Si-Bone seeks to improve patient outcomes while enhancing the efficiency of surgical procedures in the orthopedic field. Read More
SiBone (NASDAQ:SIBN) raised its full-year 2026 outlook after reporting double-digit revenue growth in the first quarter, with management pointing to new product launches, expanding physician adoption, international momentum and a proposed Medicare reimbursement change as key drivers for the year ahe
In a significant move to avert a potential financial crisis, the Federal Reserve announced in October 2025 its decision to halt its three-year Quantitative Tightening (QT) program and cut interest rates. This decisive action comes amidst growing concerns over tightening liquidity in money markets and recent market strains, signaling that
SI-BONE INC reports mixed Q2 2025 results with revenue slightly below estimates but beats on EPS, driving a positive market reaction. Strong growth and raised guidance signal confidence.
